Hematology/ Oncology and Stem Cell Therapy最新文献_第5页

Diagnosis and Treatment of Subcutaneous Panniculitis-like T-cell Lymphoma: A Systematic Literature Review. 皮下泛膜炎样t细胞淋巴瘤的诊断和治疗:系统文献综述。

Hematology/ Oncology and Stem Cell Therapy Pub Date : 2023-01-17 DOI: 10.1016/j.hemonc.2021.04.001

Dunya Yunus Alsomali, Nasir Bakshi, Mohamed Kharfan-Dabaja, Riad El Fakih, Mahmoud Aljurf

{"title":"Diagnosis and Treatment of Subcutaneous Panniculitis-like T-cell Lymphoma: A Systematic Literature Review.","authors":"Dunya Yunus Alsomali, Nasir Bakshi, Mohamed Kharfan-Dabaja, Riad El Fakih, Mahmoud Aljurf","doi":"10.1016/j.hemonc.2021.04.001","DOIUrl":"https://doi.org/10.1016/j.hemonc.2021.04.001","url":null,"abstract":"Objectives: The aim of this systematic review is to investigate different diagnostic methods and the available treatment options for subcutaneous panniculitis-like T-cell lymphoma (SPTCL).Methods: We searched PubMed, Web of Science, SCOPUS, EBSCO, and CINAHL Plus for published case reports of SPTCL. From each record, we extracted data of the diagnostic methods, immunohistochemical profile, clinical characteristics, and the treatment approaches provided. Data were summarized and narratively synthesized to highlight the various diagnostic methods and treatment options of SPTCL.Results: Our literature search yielded 1293 unique citations. Following screening, nine articles reporting a total of 15 cases were included in this systematic review. All patients presented with subcutaneous nodules. Three of the 15 cases were initially misdiagnosed. The atypical lymphoid cells were positive for CD2, CD3, granzyme B, and TIA-1 and negative for CD1a, EBER, and CD20 in all the reported cases. The atypical lymphoid cells were positive for CD45RO in four out of seven cases, positive for CD56 in three out of 12 cases tested, while positive for CD5 and CD8 in the majority of cases. Therapy ranged from topical agents to immunosuppressive agents all the way to multiagent chemotherapy.Conclusion: SPTCL is a rare lymphoma. Diagnosis is highly dependent on the immunohistochemical stains added to histopathologic and radiologic findings. Therapy is dependent on the pace of the disease, with encouraging results obtained with single-agent cyclosporine.","PeriodicalId":39226,"journal":{"name":"Hematology/ Oncology and Stem Cell Therapy","volume":"16 2","pages":"110-116"},"PeriodicalIF":0.0,"publicationDate":"2023-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.hemonc.2021.04.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10684665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10

Predicting if Lung Cancer Will Relapse-The Role of Neutrophil/Lymphocyte Ratio. 预测肺癌是否复发——中性粒细胞/淋巴细胞比值的作用。

Hematology/ Oncology and Stem Cell Therapy Pub Date : 2023-01-17 DOI: 10.1016/j.hemonc.2021.08.003

Abigail Chan, Søren Bentzen, Amit Rout, Kenneth Miller

{"title":"Predicting if Lung Cancer Will Relapse-The Role of Neutrophil/Lymphocyte Ratio.","authors":"Abigail Chan, Søren Bentzen, Amit Rout, Kenneth Miller","doi":"10.1016/j.hemonc.2021.08.003","DOIUrl":"https://doi.org/10.1016/j.hemonc.2021.08.003","url":null,"abstract":"Objective/background: Baseline neutrophil/lymphocyte ratio (NLR), a surrogate marker for systemic inflammation and immunosuppression, is a well-studied prognostic marker in non-small cell lung cancer (NSCLC). This study tests if interim NLR is prognostic in NSCLC patients in remission.Methods: This single-center, retrospective cohort study analyzed 131 NSCLC patients treated from 2010 to 2015 who achieved complete remission. NLR was calculated at baseline and from the first available blood sample during remission. Kaplan-Meier estimates of overall survival (OS) and time to recurrence were compared using the log-rank test for trend. Multivariable analysis was conducted using the Cox proportional hazards model.Results: Of the 131 cases, 63 had subsequently recurred at the last follow-up. The mean age was 64 ± 10 years. Patients with stage I (35%), II (24%), and III (41%) were included. Histology were adenocarcinoma (60%), squamous cell (33%), and unspecified (7%). The majority of patients were smokers. For the univariate analysis interim NLR was binned into tertiles, NLR < 2, 2-4.08, and > 4.08. Of those with an interim NLR > 4.08, prognosis and recurrence risk were higher. In the multivariable analysis, remission NLR was strongly prognostic for OS ( p < .001) as did patient's age ( p = .002), but not stage, race, sex, and baseline NLR.Conclusions: Our study found that interim NLR, obtained in remission, was strongly prognostic for OS and recurrence.","PeriodicalId":39226,"journal":{"name":"Hematology/ Oncology and Stem Cell Therapy","volume":"16 2","pages":"158-161"},"PeriodicalIF":0.0,"publicationDate":"2023-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10632106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Prophylactic Pretransplant Ganciclovir to Reduce Cytomegalovirus Infection After Hematopoietic Stem Cell Transplantation. 移植前预防性使用更昔洛韦减少造血干细胞移植后巨细胞病毒感染。

Hematology/ Oncology and Stem Cell Therapy Pub Date : 2023-01-12 DOI: 10.1016/j.hemonc.2021.05.001

Daniel R Reed, Gina R Petroni, Melissa West, Caroline Jones, Abeer Alfaraj, Paige G Williams, Kathlene DeGregory, Kyle Grose, Sandra Monson, Indumathy Varadarajan, Leonid Volodin, Gerald R Donowitz, Tamila L Kindwall-Keller, Karen K Ballen

{"title":"Prophylactic Pretransplant Ganciclovir to Reduce Cytomegalovirus Infection After Hematopoietic Stem Cell Transplantation.","authors":"Daniel R Reed, Gina R Petroni, Melissa West, Caroline Jones, Abeer Alfaraj, Paige G Williams, Kathlene DeGregory, Kyle Grose, Sandra Monson, Indumathy Varadarajan, Leonid Volodin, Gerald R Donowitz, Tamila L Kindwall-Keller, Karen K Ballen","doi":"10.1016/j.hemonc.2021.05.001","DOIUrl":"10.1016/j.hemonc.2021.05.001","url":null,"abstract":"Objective/background: Cytomegalovirus (CMV) reactivation remains a serious complication after allogeneic hematopoietic cell transplantation (HCT) occurring in approximately 60-70% of CMV-seropositive HCT recipients. CMV reactivation leads to adverse outcomes including end-organ damage, graft-versus-host disease, and graft failure.Methods: Ganciclovir was administered pretransplant at 5 mg/kg twice daily intravenously from the start of conditioning to Day T-2 to CMV-seropositive patients receiving their first allogeneic HCT. CMV DNA was monitored weekly until at least Day 100 posttransplant.Results: A total of 109 consecutive patients were treated, median age 57 (range 20-73) years. Of these, 36 (33%) patients had a CMV reactivation within the first 105 days posttransplant with a median time of reactivation of 52.5 (range 36-104) days posttransplant. The cumulative incidence of CMV reactivation at Day 105 posttransplant was 33.1% (95% confidence interval: 24.4-42.0). One patient developed CMV disease.Conclusion: The use of pretransplant ganciclovir was associated with low incidence of CMV reactivation and disease. These data suggest that pretransplant ganciclovir with preemptive therapy for viral reactivation may be a useful strategy to reduce CMV reactivation. Future prospective trials are needed to compare strategies for CMV prophylaxis.","PeriodicalId":39226,"journal":{"name":"Hematology/ Oncology and Stem Cell Therapy","volume":"16 1","pages":"61-69"},"PeriodicalIF":0.0,"publicationDate":"2023-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11956836/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9434797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Primary Mediastinal Large B-cell Lymphoma : Impact of Chemotherapy Choice. 原发性纵隔大b细胞淋巴瘤:化疗选择的影响。

Hematology/ Oncology and Stem Cell Therapy Pub Date : 2022-12-23 DOI: 10.1016/j.hemonc.2021.05.002

Rehab Elhagracy, Abdulaziz Hamadah, Karen Pinto, Amany Hussain, Mohammad Osmani, Salem Alshemmari

{"title":"Primary Mediastinal Large B-cell Lymphoma : Impact of Chemotherapy Choice.","authors":"Rehab Elhagracy, Abdulaziz Hamadah, Karen Pinto, Amany Hussain, Mohammad Osmani, Salem Alshemmari","doi":"10.1016/j.hemonc.2021.05.002","DOIUrl":"https://doi.org/10.1016/j.hemonc.2021.05.002","url":null,"abstract":"Objective/background: Data generated from retrospective studies on primary mediastinal B-cell lymphoma (PMBCL) outcome are valuable as no prospective phase 3 trials have been conducted in this rare type of lymphoma.Methods: Our goal was to assess the long-term outcome of 41 patients with PMBCL who were treated at the Kuwait Cancer Center. We evaluated two types of multidrug treatment, R-CHOP (rituximab, vincristine, doxorubicin, cyclophosphamide, and prednisone) and DA-EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab), and determined overall survival and complete response (CR) as primary endpoints.Results: In our cohort, 27 (66%) cases were treated with R-CHOP and 14 (34%) cases were treated with DA-EPOCH-R. The overall median follow-up time was 34 months. Among the patients treated with R-CHOP, 23 out of 27 (92.6%) patients achieved CR; similarly, 10 out of 14 patients (85.7%) in the DA-EPOCH-R group achieved CR after initial treatment. There were no differences in OS between patients treated with R-CHOP versus DA-EPOCH-R.Conclusion: The findings of this study indicate that combined chemotherapy and immunotherapy results in excellent long-term outcome of patients with PMBCL. At our center, we prefer R-CHOP to DA-EPOCH-R for low-risk patients with nonbulky disease.","PeriodicalId":39226,"journal":{"name":"Hematology/ Oncology and Stem Cell Therapy","volume":"15 4","pages":"196-200"},"PeriodicalIF":0.0,"publicationDate":"2022-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.hemonc.2021.05.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9084874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

The Impact of Post-Hematopoietic Stem Cell Transplant Tyrosine Kinase Inhibitors in Philadelphia-Positive Acute Lymphoblastic Leukemia. 造血干细胞移植后酪氨酸激酶抑制剂对费城阳性急性淋巴细胞白血病的影响。

Hematology/ Oncology and Stem Cell Therapy Pub Date : 2022-12-23 DOI: 10.1016/j.hemonc.2021.07.003

Khalid Halahleh, Dalia Al Rimawi, Amal Abu Ghosh, Isra Muradi, Waleed Da'na, Mehdi Hamadani

引用次数: 2

Leucoerythroblastic PICTURE and Bone Marrow Fibrosis: Infantile Primary Myelofibrosis. 白细胞母细胞成像与骨髓纤维化:婴儿原发性骨髓纤维化。

Hematology/ Oncology and Stem Cell Therapy Pub Date : 2022-12-23 DOI: 10.1016/j.hemonc.2021.10.002

Hasan Hashem, Nazmi Kamal

引用次数: 0

Allogeneic Chimeric Antigen Receptor T Cells for Hematologic Malignancies. 同种异体嵌合抗原受体T细胞用于血液恶性肿瘤。

Hematology/ Oncology and Stem Cell Therapy Pub Date : 2022-12-15 DOI: 10.56875/2589-0646.1030

Yang Yang, Xia Bi, Mia Gergis, Dongni Yi, Jingmei Hsu, Usama Gergis

引用次数: 2

Chimeric Antigen Receptor T-cell Therapies in Lymphoma Patients with Central Nervous System Involvement. 嵌合抗原受体t细胞治疗累及中枢神经系统的淋巴瘤。

Hematology/ Oncology and Stem Cell Therapy Pub Date : 2022-12-15 DOI: 10.56875/2589-0646.1024

Dongni Yi, Mia Gergis, Ghada Elgohary, Jingmei Hsu, Yang Yang, Xia Bi, Usama Gergis

{"title":"Chimeric Antigen Receptor T-cell Therapies in Lymphoma Patients with Central Nervous System Involvement.","authors":"Dongni Yi, Mia Gergis, Ghada Elgohary, Jingmei Hsu, Yang Yang, Xia Bi, Usama Gergis","doi":"10.56875/2589-0646.1024","DOIUrl":"https://doi.org/10.56875/2589-0646.1024","url":null,"abstract":"Background and objective: CAR T-cell therapy has significantly improved the outcomes of patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). However, most clinical trials excluded patients with central nervous system (CNS) involvement due to uncertain efficacy and safety.Material and methods: On January 1, 2022, we searched PubMed to identify all published literature associated with current commercial CAR T-cell therapies for B-NHL, including tisagenlecleucel (tisa-cel), axicabtagene ciloleucel (axi-cel), brexucabtagene autoleucel (brexu-cel), and lisocabtagene maraleucel (liso-cel). Studies that involved patients with either primary or secondary CNS lymphoma, and evaluated response rate, adverse events (AEs), or survival were included and summarized.Result: Herein, we summarize the results of 11 studies qualified for our inclusion criteria, reporting 58 lymphoma patients with CNS Involvement with 44 evaluable for clinical response, 25 for immune effector cell-associated neurotoxicity syndrome (ICANS) and 48 for Cytokine release syndrome (CRS). Objective response was achieved in 62% (16/26) of patients, and CR was achieved in 52% (23/44) of patients. Forty-four percent (11/25) developed ICANS, and 35% (17/48) developed severe ICANS (grade≥3). CRS was reported in 63% (15/24) of patients, while severe CRS (grade≥3) was reported in 7% (3/42) of patients.Conclusion: Based on our PubMed literature review, we conclude that CAR T-cell therapy may benefit patients with CNS lymphoma with promising response rates and acceptable AE. However, definite conclusions cannot be drawn until data with a larger sample size is available.","PeriodicalId":39226,"journal":{"name":"Hematology/ Oncology and Stem Cell Therapy","volume":"15 3","pages":"66-72"},"PeriodicalIF":0.0,"publicationDate":"2022-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10405867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Chimeric Antigen Receptor T Cell Therapy For Solid Tumors. 嵌合抗原受体T细胞治疗实体瘤。

Hematology/ Oncology and Stem Cell Therapy Pub Date : 2022-12-15 DOI: 10.56875/2589-0646.1028

Jingmei Hsu, Yang Yang, Mia Gergis, Xia Bi, Dongni Yi, Usama Gergis

引用次数: 0

CAR-T cell Therapies for B-cell Lymphoid Malignancies: Identifying Targets Beyond CD19. b淋巴细胞恶性肿瘤的CAR-T细胞疗法:识别CD19以外的靶标。

Hematology/ Oncology and Stem Cell Therapy Pub Date : 2022-12-15 DOI: 10.56875/2589-0646.1026

Yenny M Vanegas, Razan Mohty, Martha E Gadd, Yan Luo, Mahmoud Aljurf, Hong Qin, Mohamed A Kharfan-Dabaja

{"title":"CAR-T cell Therapies for B-cell Lymphoid Malignancies: Identifying Targets Beyond CD19.","authors":"Yenny M Vanegas, Razan Mohty, Martha E Gadd, Yan Luo, Mahmoud Aljurf, Hong Qin, Mohamed A Kharfan-Dabaja","doi":"10.56875/2589-0646.1026","DOIUrl":"https://doi.org/10.56875/2589-0646.1026","url":null,"abstract":"Chimeric antigen receptors (CARs) are synthetic engineered receptors with an antigen recognition domain derived from a high-specificity monoclonal antibody that can target surface molecules on tumor cells. T cells are genetically engineered to express CARs, thereby harnessing the antigen-recognition ability of antibodies and effector function of T cells. Target surface molecule selection is crucial for manufacturing CARs. Ideally, a target surface molecule should be restricted to tumor cells and minimally expressed or absent on normal tissues. Different CD19-targeted CAR-T cell therapies have been approved for the treatment of B-cell lymphoid malignancies that are refractory to other therapies, including indolent and aggressive B-cell non-Hodgkin lymphomas (NHL) and B-cell acute lymphoblastic leukemia (B-ALL). Despite impressive results, many patients with aggressive and refractory B-cell malignancies do not respond to or relapse after CD19 CAR-T cell therapies. Thus, several additional strategies are currently being evaluated to overcome these limitations. This review discusses studies on other promising CAR-T cell targets, including CD20, CD22, BAFF-R, ROR1, CD70, BCR complex, kappa/lambda light chains, multitargeted CAR-T cells, and combinations of CAR-T cell therapy with different drugs.","PeriodicalId":39226,"journal":{"name":"Hematology/ Oncology and Stem Cell Therapy","volume":"15 3","pages":"81-93"},"PeriodicalIF":0.0,"publicationDate":"2022-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10414036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1